Related Experiment Video
Updated: Mar 13, 2026
Isolation and Functional Assessment of Human Breast Cancer Stem Cells from Cell and Tissue Samples
Published on: October 2, 2020
CDK4 regulates cancer stemness and is a novel therapeutic target for triple-negative breast cancer
Meiou Dai1, Chenjing Zhang1, Ayad Ali1
1Department of Medicine, McGill University Health Center, Cancer Research Program, Montreal, Quebec, H4A 3J1, Canada.
Abstract:
Triple negative breast cancers exhibit very aggressive features and poor patient outcomes. These tumors are enriched in cancer stem cells and exhibit resistance to most treatments and chemotherapy. In this study, we found the cyclin-dependent kinase (CDK4) to act as a cancer stem cell regulator and novel prognostic marker in triple negative breast cancers. We found CDK4 to be highly expressed in these tumors and its expression to correlate with poor overall and relapse free survival outcomes, high tumor grade and poor prognostic features of triple negative breast cancer patients. Moreover, we found that blocking CDK4 expression or kinase activity, using a pharmacological inhibitor prevented breast cancer stem cell self-renewal. Interestingly, suppression of CDK4 expression or kinase activity reversed the basal-B TNBC mesenchymal phenotype to an epithelial- and luminal-like phenotype which correlates with better clinical prognosis. Finally, blocking CDK4 activity efficiently eliminated both normal and chemotherapy-resistant cancer cells in triple negative breast cancers, highlighting CDK4 as a promising novel therapeutic target for these aggressive breast tumors.
Insights
Cyclin-dependent kinase 4 (CDK4) drives aggressive triple-negative breast cancer stem cell renewal and poor survival. Inhibiting CDK4 eradicates cancer cells and improves prognosis, marking it a promising therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Triple-negative breast cancer (TNBC) is aggressive with poor patient outcomes.
- TNBC tumors are characterized by cancer stem cells and treatment resistance.
- Identifying novel therapeutic targets and prognostic markers for TNBC is critical.
Purpose of the Study:
- To investigate the role of cyclin-dependent kinase 4 (CDK4) in TNBC.
- To evaluate CDK4 as a prognostic marker and therapeutic target in TNBC.
Main Methods:
- Analysis of CDK4 expression in TNBC patient tumors.
- Correlation of CDK4 expression with clinical outcomes and tumor grade.
- Inhibition of CDK4 using pharmacological inhibitors in vitro.
- Assessment of effects on cancer stem cell self-renewal and phenotype.
Main Results:
- CDK4 is highly expressed in TNBC and correlates with poor survival and high tumor grade.
- Pharmacological inhibition of CDK4 prevents cancer stem cell self-renewal.
- Suppression of CDK4 reverses the mesenchymal phenotype to an epithelial-like phenotype, improving prognosis.
- CDK4 inhibition eliminates both normal and chemotherapy-resistant TNBC cells.
Conclusions:
- CDK4 acts as a crucial regulator of cancer stem cells in TNBC.
- CDK4 is a novel prognostic marker for triple-negative breast cancer.
- Targeting CDK4 represents a promising therapeutic strategy for aggressive TNBC.
Related Concept Videos
02:34Inhibition of Cdk Activity
02:34Inhibition of CDK Activity
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:57Targeted Cancer Therapies
02:40Cancer Stem Cells and Tumor Maintenance
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...